Parse Biosciences Launches Certified Service Provider Program
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of its Certified Service Provider (CSP) Program. For researchers who are seeking paths to outsource their single cell projects, Parse’s CSP Program provides options to partner with trusted service providers capable of running smaller pilot projects up to performing routine high throughput projects.
Fremont, California-based SeqMatic and Framingham, Massachusetts-based Eurofins Clinical Enterprise, LLC are the first CSPs to partner with Parse to offer its expanding portfolio of single cell products, including its Evercode™ Whole Transcriptome, Evercode™ TCR, CRISPR Detect, Gene Capture, and its recently released Evercode™ BCR, which captures full length BCR sequences and gene expression together at unprecedented scale.
“The advances we’re seeing as a result of single cell sequencing continue to transform scientific research,” noted Parse co-founder and CEO Alex Rosenberg. “The CSP Program is an important step in broadening access to scalable single cell sequencing, and we’re proud to have SeqMatic and Eurofins Clinical Enterprise join us as our first partners in this initiative.”
Comprehensive CSPs providing a full range of high quality end-to-end multi omics workflow solutions including DNA and RNA sequencing, SeqMatic and Eurofins Clinical Enterprise can manage samples from any US or international location, including multi-site collaborations and unique requirements. Their professional service provides assurance of expert handling, tracking and coordination of samples.
“SeqMatic is dedicated to providing the highest level of service and cutting edge technologies to our more than 700 customers in the US and around the world,” said SeqMatic CEO Len Goren. “We are excited to make Parse’s industry-leading single cell sequencing kits available to all of them.”
Partner companies like SeqMatic and Eurofins Clinical Enterprise that offer Parse’s kits as a service must meet Parse’s stringent criteria and provide the highest quality results to their clients. For more information about Parse’s CSP program, visit https://www.parsebiosciences.com/service-providers/. To learn more about SeqMatic’s Parse offerings, visit https://www.seqmatic.com/services/parse-biosciences-single-cell-rna-sequencing-service/, and to learn more about Eurofins Clinical Enterprise’s Parse offerings, visit https://clinicalenterprise.com/.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for data analysis.
Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711445815/en/
Contacts
Jay Roberts, SRPR
jay@shevrushpr.com | 917.696.2142
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Signs Contract for Engineering of AP1000 ® Reactors in Bulgaria4.11.2024 21:12:00 CET | Press Release
Westinghouse Electric Company, Hyundai Engineering & Construction Co. and Bulgaria’s Kozloduy NPP - New Build EAD today signed the Engineering Services Contract for two AP1000® reactors to be built at the Kozloduy site. Bulgarian Prime Minister Dimitar Glavchev, Bulgarian Minister of Energy Vladimir Malinov, U.S. Ambassador to Bulgaria Kenneth Merten, Executive Director of Kozloduy NPP - New Build Petyo Ivanov, Senior Vice President of Westinghouse Energy Systems Elias Gedeon, and Hyundai Engineering & Construction President and CEO Yoon Young-Joon attended the signing ceremony in Sofia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104293861/en/ Following the signing ceremony. From left: Yoon Young-Joon, President and CEO, Hyundai Engineering & Construction; Ji I Cho, Deputy Head of Mission and Charge d'Affaires a.i., Embassy of the Republic of Korea; Vladimir Malinov, Minister of Energy, Bulgaria; Dimitar Glavchev, Pri
Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings4.11.2024 20:50:00 CET | Press Release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/ Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire) “Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executiv
Earnix Survey Reveals Majority of Insurers Plan to Implement AI Predictive Models Within Two Years4.11.2024 17:10:00 CET | Press Release
Earnix, the leading AI, real-time platform for intelligent decisioning SaaS solutions for the insurance and financial services industries, today announced its third annual survey on the state of the insurance market, the 2024 Industry Trends Report. The survey of over 400 global insurance executives uncovers key findings, trends, implications for what’s next in insurance, and sheds light on the role technology can play in shaping a better future. Key findings from the 2024 survey include: More than two-thirds (70%) of respondents expect to deploy AI models that make predictions based on real-time data in the next two years More than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year 58% of respondents take more than 5 months to implement a rule change and 21% take longer than 7 months Insurers still need to move beyond legacy systems and fully modernize their operations, yet 49% admit they are behind schedule “This year’s su
Parse Biosciences Launches Evercode Low Input Fixation for Cells and Nuclei4.11.2024 17:00:00 CET | Press Release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch and availability of Evercode™ Low Input Fixation kits for both cells and nuclei. The new kits empower researchers who have a small number of starting cells or nuclei who ordinarily might not be able to perform single cell sequencing using fixed cells. Fixation is a strategy used by many single cell researchers because it enables them to collect samples at different times and then perform library preparation and sequencing at once when all of the samples are amassed. Yet, a well-known challenge across all fixation technologies is that they require a certain number of cells or nuclei, usually 50,000 or greater. With the new kits from Parse, researchers can start with as few as 10,000 cells or nuclei. The new low input fixation kits are ideal for researchers working with limited cells across various conditions or those handling rare and precious samples. These kits
Blackmoor Investment Partners Strengthens Its PE Capabilities as It Attracts Investment and Expands Its Senior Team to Pursue Ambitious Growth Plans4.11.2024 15:15:00 CET | Press Release
Blackmoor Investment Partners (“Blackmoor”), a long-term equity investor and active owner of high quality European public companies with significant improvement potential, has attracted investment from and appointed Alex Savin as Senior Partner. Blackmoor was founded by Douglas Smith and Guido Schmidt-Chiari in 2017 to deliver superior returns to its investors by deploying private equity best practices to implement value creation strategies at its investee companies. Since inception, it has made over 25 core investments, having initiated and implemented change programs across its portfolio, significantly outperforming relevant benchmarks. Alex Savin brings extensive private equity experience, having worked at Bain & Company’s Private Equity practice in London and Boston, and co-founding one of the most successful private equity firms in Central and Eastern Europe, which was backed by global institutional investors and delivered outstanding results. Prior to joining Blackmoor, he led Ch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom